P-G Qiao1, H-T Zhang2, J Zhou3, M Li4, J-L Ma5, N Tian6, X-D Xing7, G-J Li8. 1. Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, #8 Fengtai dong street, Fengtai District, Beijing, 100071, China. qiaopenggang@sina.com. 2. Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, #8 Fengtai dong street, Fengtai District, Beijing, 100071, China. zhanghongtao192@sina.com. 3. Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, #8 Fengtai dong street, Fengtai District, Beijing, 100071, China. zjuan122@163.com. 4. Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, #8 Fengtai dong street, Fengtai District, Beijing, 100071, China. 634436934@qq.com. 5. Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, #8 Fengtai dong street, Fengtai District, Beijing, 100071, China. 46417992@qq.com. 6. Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, #8 Fengtai dong street, Fengtai District, Beijing, 100071, China. tianning331@gmail.com. 7. Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, #8 Fengtai dong street, Fengtai District, Beijing, 100071, China. 307xxd@163.com. 8. Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, #8 Fengtai dong street, Fengtai District, Beijing, 100071, China. ligj307@sina.com.
Abstract
PURPOSE: To study the feasibility and clinical value of dynamic contrast-enhanced (DCE) computed tomography (CT) for early evaluation of targeted therapy efficacy in non-small cell lung cancer (NSCLC). METHODS: We measured tumor diameter, peak height (PH), time to peak (TP), tumor mass-aortic peak height ratio (M/A), and blood perfusion (BP) in 20 patients with advanced NSCLC using DCE-CT before and 7 days after treatment. Therapy efficacy was assessed with conventional CT 4-6 weeks post-treatment. RESULTS: Patients were grouped into those with partial response (PR), stable disease (SD), and progressive disease (PD) according to the therapy efficacy assessment at 4-6 weeks post-treatment. The PR group primary tumor diameter (P = 0.0007) and BP (P = 0.0225) were reduced at 7 days post-treatment; the SD group DCE-CT value changes were not significant. The PD group M/A (P = 0.0443) and BP (P = 0.0268) were increased 7 days post-treatment. The BP decrease group had significantly longer progression-free survival than the BP increase group (median, 54 vs. 6 weeks). CONCLUSION: DCE-CT can evaluate targeted therapy efficacy at 7 days post-treatment. Decreased primary tumor diameter and BP indicate tumor sensitivity to therapy; increased BP with unchanged tumor diameter suggests the tumor is not sensitive to therapy. Reduced BP suggests treatment effectiveness.
PURPOSE: To study the feasibility and clinical value of dynamic contrast-enhanced (DCE) computed tomography (CT) for early evaluation of targeted therapy efficacy in non-small cell lung cancer (NSCLC). METHODS: We measured tumor diameter, peak height (PH), time to peak (TP), tumor mass-aortic peak height ratio (M/A), and blood perfusion (BP) in 20 patients with advanced NSCLC using DCE-CT before and 7 days after treatment. Therapy efficacy was assessed with conventional CT 4-6 weeks post-treatment. RESULTS:Patients were grouped into those with partial response (PR), stable disease (SD), and progressive disease (PD) according to the therapy efficacy assessment at 4-6 weeks post-treatment. The PR group primary tumor diameter (P = 0.0007) and BP (P = 0.0225) were reduced at 7 days post-treatment; the SD group DCE-CT value changes were not significant. The PD group M/A (P = 0.0443) and BP (P = 0.0268) were increased 7 days post-treatment. The BP decrease group had significantly longer progression-free survival than the BP increase group (median, 54 vs. 6 weeks). CONCLUSION:DCE-CT can evaluate targeted therapy efficacy at 7 days post-treatment. Decreased primary tumor diameter and BP indicate tumor sensitivity to therapy; increased BP with unchanged tumor diameter suggests the tumor is not sensitive to therapy. Reduced BP suggests treatment effectiveness.
Authors: Edwin A Usmanij; Lioe-Fee de Geus-Oei; Esther G C Troost; Liesbeth Peters-Bax; Erik H F M van der Heijden; Johannes H A M Kaanders; Wim J G Oyen; Olga C J Schuurbiers; Johan Bussink Journal: J Nucl Med Date: 2013-07-17 Impact factor: 10.057
Authors: Jeremy J Erasmus; Gregory W Gladish; Lyle Broemeling; Bradley S Sabloff; Mylene T Truong; Roy S Herbst; Reginald F Munden Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: M Satouchi; S Negoro; Y Funada; Y Urata; T Shimada; S Yoshimura; Y Kotani; T Sakuma; H Watanabe; S Adachi; Y Takada; Y Yatabe; T Mitsudomi Journal: Br J Cancer Date: 2007-03-27 Impact factor: 7.640
Authors: Louise S Strauch; Rie Ø Eriksen; Michael Sandgaard; Thomas S Kristensen; Michael B Nielsen; Carsten A Lauridsen Journal: Diagnostics (Basel) Date: 2016-07-21